ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Biologic agents"

  • Abstract Number: 036 • 2020 Pediatric Rheumatology Symposium

    Medication Related Decision-Making in Parents of Children with Juvenile Idiopathic Arthritis

    Alexandra Munroe1, Adam Huber 2, Bianca Lang 3, Suzanne Ramsey 4 and Elizabeth Stringer 4, 1Dalhousie University, Halifax, Nova Scotia, Canada, 2IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, 3Dalhousie University - Halifax, Halifax, Canada, 4IWK Health Centre, Halifax, Canada

    Background/Purpose: Outcomes for juvenile idiopathic arthritis (JIA) have improved with use of disease-modifying anti-rheumatic drugs (DMARDs) and biologics. Despite this, the decision by a parent…
  • Abstract Number: 092 • 2020 Pediatric Rheumatology Symposium

    The Initial Treatment of Systemic Juvenile Idiopathic Arthritis: An International Collaboration Among 10 Registries

    Mary Beth Son1, Yukiko Kimura 2, Kristiina Aalto 3, Lillemor Berntson 4, Johnathan Dallas 1, Ciaran Duffy 5, Mia Glerup 6, Jaime Guzman 7, Troels Herlin 8, Petteri Hovi 9, Kimme Hyrich 10, Jens Klotsche 11, Bo Magnusson 12, Vanessa McIntyre 13, Ellen Nordal 14, Seza Ozen 15, Maria Jose Santos 16, Betul Sozeri 17 and Timothy Beukelman 18, 1Boston Children's Hospital, Boston, Massachusetts, 2Hackensack Meridian School of Medicine, Hackensack, 3Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., HUS, Finland, 4Department of Womens and Childrens Health, Uppsala University, Uppsala, Sweden., Uppsala, Sweden, 5Ottawa, Canada, 6Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, 7University of British Columbia and BC Children's Hospital, Vancouver, Canada, 8Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark., Aarhus N, Denmark, 9Helsinki University Hospital, Helsinki, Finland, 10Manchester, United Kingdom, 11Berlin, Germany, 12Karolinska University Hospital, Stockholm, Sweden, 13Manchester University, Manchester UK, United Kingdom, 14Department of Pediatrics, University Hospital of North Norway, and Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway., Tromsø, Norway, 15Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, 16Portugal, 17Boston, Turkey, 18University of Alabama at Birmingham, Birmingham

    Background/Purpose: The introduction of biologic medications has revolutionized the care of children with systemic juvenile idiopathic arthritis (SJIA). Differences in treatment approaches among different countries…
  • Abstract Number: 137 • 2020 Pediatric Rheumatology Symposium

    Measuring Decision Conflict in Parents of Children with Juvenile Idiopathic Arthritis When Making the Decision to Begin Disease Modifying Anti-Rheumatic Drugs or Biologic Agents

    Chelsea DeCoste1, Suzanne Ramsey 2, Adam Huber 3, Bianca Lang 4 and Elizabeth Stringer 2, 1The Hospital for Sick Children, Toronto, Canada, 2IWK Health Centre, Halifax, Canada, 3IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, 4Dalhousie University - Halifax, Halifax, Canada

    Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) and biologic agents are routinely used in the treatment of JIA and JIA-associated uveitis (JIA-AU). Parents are often fearful, however,…
  • Abstract Number: L19 • 2019 ACR/ARP Annual Meeting

    Ianalumab (VAY736), a Dual Mode of Action Biologic Combining BAFF Receptor Inhibition with B Cell Depletion, for Treatment of Primary Sjögren’s Syndrome: Results of an International Randomized, Placebo Controlled Dose Range Finding Study in 190 Patients

    Simon Bowman1, Robert Fox 2, Thomas Dörner 3, Xavier Mariette 4, Athena Papas 5, Thomas Grader-Beck 6, Benjamin A. Fisher 7, Filipe Barcelos 8, Salvatore De Vita 9, Hendrik Schulze-Koops 10, Robert J. Moots 11, Guido Junge 12, Janice Woznicki 13, Monika Sopala 12, Wen-Lin Luo 13 and Wolfgang Hueber 12, 1University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, 2Scripps Memorial Hospital and Research Institute, La Jolla, California, 3Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany, 4Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, 5Tufts School of Dental Medicine, Massachusetts, 6Johns Hopkins University, Baltimore, 7University Hospitals Birmingham NHS Foundation Trust, Birmingham Biomedical Research Centre, Birmingham, United Kingdom, 8Nova Medical School, Hospital Cuf Descobertas, Instituto Português de Reumatologia,, Lisbon, Portugal, 9Rheumatology Clinic, Udine University Hospital, Department of Medical Area, University of Udine, Udine, Italy, Udine, Italy, 10Department of Rheumatology/Clinical Immunology, Ludwig-Maximilians-University Munich, Munich, Germany, 11Institute of Ageing and Chronic Disease, Liverpool, United Kingdom, 12Novartis Pharma AG, basel, Switzerland, 13Novartis Pharmaceuticals Corporation, New Jersey

    Background/Purpose: Primary Sjogren’s syndrome (pSS) is a multi-organ autoimmune disease primarily affecting excretory glands and characterized by B-cell hyperactivity. No approved systemic treatments are available.…
  • Abstract Number: 1519 • 2019 ACR/ARP Annual Meeting

    Predicting Response to Biologic Therapy in Patients with Axial Spondyloarthritis (axSpA)

    Gareth Jones1, Linda Dean 1, Ejaz Pathan 2 and Gary Macfarlane 1, 1University of Aberdeen, Aberdeen, United Kingdom, 2Toronto Western Hospital, Toronto, Canada

    Background/Purpose: In axial spondyloarthritis (axSpA), the clinical benefits of TNF inhibition (TNFi) are well documented although, by design, most studies report average benefits in groups…
  • Abstract Number: 1751 • 2019 ACR/ARP Annual Meeting

    A Systematic Literature Review of Efficacy and Safety of Biologic Agents for the Treatment of Juvenile Dermatomyositis

    edoardo marrani1, Sarah Abu Rumeileh 1, Francesca Tirelli 2, Ilaria Maccora 3 and Gabriele Simonini 4, 1Post graduate School of pediatrics, University of Florence, Firenze, Italy, 2Post Graduate School of Pediatrics, University of Florence, Florence, Italy, Firenze, Italy, 3Post Graduate School of Pediatrics, University of Florence, Florence, Italy, Florence, Toscana, Italy, 4Anna Meyer Children's Hospital, Flotence, Italy

    Background/Purpose: Juvenile dermatomyositis (JDM) is a rare, chronic autoimmune illness characterized by symmetric, proximal muscle damages and involvement of the skin. While first line treatment…
  • Abstract Number: 1802 • 2019 ACR/ARP Annual Meeting

    Utility of Repeat Latent Tuberculosis Testing in Patients Taking Biologics

    Urmi Khanna1, Ariana Ellis 2, AbdulAziz Galadari 3, Jeffery Hu 4, Josh Gallop 5, M. Elaine Husni 6 and Anthony Fernandez 7, 1Department of Dermatology , Cleveland Clinic, Cleveland, OH, 2Northeast Ohio Medical University, Cleveland, OH, 3Cleveland Clinic, Abu Dhabi, Cleveland, 4Case Western Reserve University, Cleveland, 5Cleveland Clinic Lerner College of Medicine, Cleveland, OH, 6Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, 7Department of Dermatology and Pathology, Cleveland Clinic, Cleveland, OH

    Background/Purpose: Guidelines for repeat Latent Tuberculosis Infection (LTBI) testing while on biologics are not clearly defined. The American College of Rheumatology recommends repeat LTBI screening…
  • Abstract Number: 1822 • 2019 ACR/ARP Annual Meeting

    6 and 12-month Drug Retention Rates and Treatment Outcomes in 941 Patients with Axial Spondyloarthritis Treated with Secukinumab in Routine Clinical Practice in 12 European Countries in the EuroSpA Research Collaboration Network

    Brigitte Michelsen1, Johan Askling 2, Catalin Codreanu 3, Herman Mann 4, Anne Gitte Loft 5, Manuel Pombo-Suarez 6, Ziga Rotar 7, Tore Kvien 8, Maria José Santos 9, Anna Mari Hokkanen 10, Florenzo Iannone 11, Bjorn Gudbjornsson 12, Fatos Onen 13, Lennart Jacobsson 14, Ruxandra IONESCU 15, Karel Pavelka 4, Carlos Sánchez-Piedra 16, Matija Tomsic 17, Joe Sexton 18, Helena Santos 19, Jenny Österlund 20, Alberto Cauli 21, Arni Jon Geirsson 22, Servet Akar 23, Adrian Ciurea 24, Gareth Jones 25, Irene van der Horst-Bruinsma 26, Cecilie Heegaard Brahe 27, Stylianos Georgiadis 28, Lykke Midtbøll Ørnbjerg 27, Mikkel Østergaard 29 and Merete Lund Hetland 30, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark/ Hospital of Southern Norway Trust, Kristiansand, Norway/ Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 2Karolinska Institutet, Stockholm, Sweden, 3Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, 4Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, 5Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, 6Unit Research, Spanish Society of Rheumatology, Madrid, Spain, 7UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, 8Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, 9Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, 10Helsinki University Hospital, Helsinki, Finland, 11Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, 12Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 13Dokuz Eylul University School of Medicine, Division of Rheumatology, İzmir, Turkey, 14Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden, 15SPITALUL CLINIC SFANTA MARIA, Bucharest, 16Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 17Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, 18Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, 19Instituto Português de Reumatologia (IPR), Lisbon, Portugal, 20ROB-FIN registry, Helsinki University and Helsinki University Hospital, Helsinki, Finland, 21Universitá di Cagliari, Cagliari, Italy, 22Centre for Rheumatology Research, University Hospital and Faculty of Medicine, Reykjavik, Iceland, 23Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, 24University Hospital Zürich, Zürich, Switzerland, 25University of Aberdeen, Aberdeen, United Kingdom, 26Amsterdam University Medical Center, Amsterdam, Netherlands, 27Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, 28DANBIO registry and Copenhagen Center for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, 29Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, 30DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark

    Background/Purpose: Secukinumab is a fully human IgG1 monoclonal antibody targeting interleukin-17A. There is a lack of real-life evidence on secukinumab retention rates and treatment outcomes…
  • Abstract Number: 2099 • 2019 ACR/ARP Annual Meeting

    Comparison of Single and Dual Latent Tuberculosis Screening Strategies Before the Initiation of Biologic and Targeted Therapy in Rheumatological Patients in Hong Kong

    Yan Ki Tang1, Ho So 2, Weng Nga Virginia Lao 2, Hin Ting Pang 2, Tak Lung Victor Wong 2, Tsz Ho Luk 2 and Man Lung Ronald Yip 3, 1Department of Medicine and Geriatrics, Kwong Wah Hospital, Hong Kong, Hong Kong, 2Department of Medicine & geriatrics, Kwong Wah Hospital, Hong Kong, Hong Kong, 3Tung Wah Group of Hospitals Integrated Diagnostic and Medical Centre, Hong Kong, Hong Kong

    Background/Purpose: Screening for latent tuberculosis infection (LTBI) before the initiation of biologic and targeted synthetic disease modifying anti-rheumatic drugs (b/tsDMARDs) is recommended internationally especially in…
  • Abstract Number: 2131 • 2019 ACR/ARP Annual Meeting

    Rituximab Safety and Persistence in Patients with Systemic Autoimmune Diseases

    Cristóbal Pavez Perales1, Jorge Juan Fragio Gil 1, Roxana Gonzalez Mazarío 1, José Ivorra Cortés 1, Elena Grau García 1, Cristina Alcañiz Escandell 1, Inmaculada Chalmeta Verdejo 1, Marta de la Rubia Navarro 1, Luis González Puig 1, Isabel Martínez Cordellat 1, Rosa Negueroles Albuixech 1, José Eloy Oller Rodríguez 2, Francisco Miguel Ortiz-Sanjuán 1, Elvira Vicens Bernabeu 1, Carmen Nájera Herranz 1, Inés Cánovas Olmos 1, Samuel Leal Rodriguez 1 and José Andrés Román Ivorra 1, 1Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, 2Rheumatology Department. HUP La Fe, v, Comunidad Valenciana, Spain

    Background/Purpose: Rituximab (RTX), an anti-CD20 monoclonal antibody inducing B cell depletion, is used as therapy for diverse systemic autoimmune diseases (SAIDs), but is associated with adverse events…
  • Abstract Number: 314 • 2019 ACR/ARP Annual Meeting

    Pre-treatment Screening for Hepatitis B and C Among Users of Biologics or New Synthetic Disease Modifying Drugs: An Analysis Using RISE Data

    Jing Li 1, Julia Kay 1, Jinoos Yazdany 1 and Gabriela Schmajuk2, 1UCSF Division of Rheumatology, San Francisco, CA, 2UCSF, SFVAMC Division of Rheumatology, San Francisco, CA

    Background/Purpose: Testing for hepatitis B virus (HBV) and hepatitis C virus (HCV) is recommended for patients initiating biologics or new synthetic DMARDs, which can increase the risk…
  • Abstract Number: 315 • 2019 ACR/ARP Annual Meeting

    Improving the Rate of Tuberculosis Screening Among High Risk Rheumatoid Arthritis Patients on Biologic Agents Using a Proposed Questionnaire

    Hamayon Babary1, Suraiya Afroz 1, John Carter 1, Yih Lin 1, Marie O'Brien 2, Marcos Maldonado 1, Helen Bateman 1, Gabriela Montes-Rivera 1, Grace Berlin 2, Dan Tseytlin 2, Madeline MacDonald 3, Yasmin Ayoubi 4, Matthew Nguyen 4, Shalini Setty 4, Rahul Mhaskar 4 and Joanne Valeriano-Marcet 1, 1University of South Florida Division of Rheumatology, Tampa, FL, 2Lehigh Valley Health Network, Allentown, PA, 3University of South Florida, College of Medicine, Tampa, FL, 4University of South Florida College of Medicine, Tampa, FL

    Background/Purpose: The use of biologics has transformed the treatment paradigm for RA; however, reactivation of Mycobacterium Tuberculosis is still a concern. Frequent TB screenings without…
  • Abstract Number: 571 • 2019 ACR/ARP Annual Meeting

    Effect of Long-term Treatment with TNF-α Inhibitor on Lipid Profile in Spondyloarthritis: Data from Nationwide Korean College of Rheumatology Biologics (KOBIO) Registry

    Jina Yeo1, Mi Ryoung Seo 1, Hee Jung Ryu 1, Hyo-Jin Choi 1 and Han Joo Baek 1, 1Division of Rheumatology / Department of Internal Medicine / Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea

    Background/Purpose: In spondyloarthritis (SpA), the lipid profile changes due to the systemic inflammatory response. Theoretically, the proinflammatory state is associated with a decrease in total…
  • Abstract Number: 752 • 2019 ACR/ARP Annual Meeting

    Drug Retention and Discontinuation Reasons Between Seven Biologics in Patients with Takayasu Arteritis

    Corrado Campochiaro1, Alessandro Tomelleri 2, Silvia Sartorelli 3, Giulio Cavalli 2, De Luca Giacomo 4, Elena Baldissera 2 and Lorenzo Dagna 2, 1Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy, 2Unit of Immunology, Rheumatology, Allergy and Rare Diseases. IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University., Milan, Italy, 3Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, Italy, 4Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy., Milan, Italy

    Background/Purpose: Takayasu's arteritis (TA) is a large vessel vasculitis affecting mainly young women. Biologic agents are currently use to treat refractory TA patients but no…
  • Abstract Number: 932 • 2019 ACR/ARP Annual Meeting

    Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in MTX-IR Patients with Rheumatoid Arthritis

    Yoshiya Tanaka1, Tsutomu Takeuchi 2, Hisashi Yamanaka 3, Toshihiro Nanki 4, Hisanori Umehara 5, Nobuyuki Yasuda 6, Fumitoshi Tago 7, Yasumi Kitahara 8, Makoto Kawakubo 7, Kentaro Torii 8, Seiichiro Hojo 8, Tetsu Kawano 6 and Toshio Imai 6, 1University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 2Keio University School of Medicine, Tokyo, Japan, 3Sanno Medical Center, Minato-ku, Tokyo, Japan, 4Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan, 5Nagahama City Hospital / Division of Rheumatology and Immunology, Nagahama, Japan, 6KAN Research Institute, Inc., Kobe, Japan, 7Eisai Co., Ltd., Tokyo, Japan, 8Eisai Co., Ltd., Bunkyo-ku, Japan

    Background/Purpose: Fractalkine (CX3CL1, designated as FKN hereafter) is the sole member of the CX3C-chemokine which leads to dual actions, chemotaxis and cell adhesion for leukocytes…
  • 1
  • 2
  • 3
  • …
  • 26
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies